Similar Papers

Paper Title
Journal
Date
Author
EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers.
Tania Crombet Ramos ... Carmen Viada
Journal of Clinical Oncology | VOL. 31
Tania Crombet Ramos, et. al.Tania Crombet Ramos ... Carmen Viada
20 May 2013
Abstract 1196: BALF liquid biopsy provides a novel platform for speedy and accurate EGFR mutation testing in advanced NSCLC patients
In Ae Kim ... Jae Young Hur
Cancer Research | VOL. 81
In Ae Kim, et. al.In Ae Kim ... Jae Young Hur
01 Jul 2021
782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2nd line anti-PD1/L1 monotherapy in the PIONeeR project
...
Journal for ImmunoTherapy of Cancer | VOL. 11
, et. al. ...
31 Oct 2023
7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial
...
Annals of Oncology | VOL. 33
, et. al. ...
01 Apr 2022
View more papers

More From: Lung Cancer

Paper Title
Journal
Date
Author
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database
Koki Fujii ... Hidenori Kage
Lung Cancer | VOL. -
Koki Fujii, et. al.Koki Fujii ... Hidenori Kage
01 Jan 2025
Evaluating tumour budding could improve the new grading system for lung adenocarcinoma
Kirsi K Volmonen ... Aija H Knuuttila
Lung Cancer | VOL. 199
Kirsi K Volmonen, et. al.Kirsi K Volmonen ... Aija H Knuuttila
01 Jan 2025
Sunvozertinib monotherapy in EGFR tyrosine kinase Inhibitor-Resistant Non-Small cell lung cancer with EGFR mutations
Mengzhao Wang ... James Chih-Hsin Yang
Lung Cancer | VOL. 199
Mengzhao Wang, et. al.Mengzhao Wang ... James Chih-Hsin Yang
01 Jan 2025
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
Mingying Wu ... Yuzhou Wang
Lung Cancer | VOL. 199
Mingying Wu, et. al.Mingying Wu ... Yuzhou Wang
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.